OptoRhythm is pioneering a novel, light-based approach to heart rhythm control.Founded on over 20 years of groundbreaking research by Prof. Lior Gepstein (CSO & Co-Founder), a global leader in cardiac electrophysiology and optogenetics, OptoRhythm is transforming Atrial Fibrillation (AF) treatment. Our technology combines optogenetic gene therapy with an implantable micro-LED array to create the world’s first Optic Defibrillator. Unlike traditional electric shock methods, OptoRhythm’s Optic Defibrillator painlessly stops chaotic atrial contractions using precise light pulses. This real-time, repeatable, non-destructive solution addresses current AF treatment limitations, providing long-term rhythm control and improving patient outcomes.https://ngt-healthcare2.com/optorhythm/

Reviewing, analyzing, developing, and presenting written opinions on projects seeking funding fromthe NGT incubator.

Giving business consulting to Technion scientists to prepare proposals for the KAMIN incentiveprogram funded by the Israel Innovation Authority.

A Digital therapeutics startup company developing software-drug combinations.• Analyzed multiple markets and provided valuable insights that shaped the company's direction.• Led the development of a theory explaining how our app synergizes with immunotherapy drugs.• Involved in planning clinical trials to test proposed theory among oncology patients.• Created scientific and business materials like one-pagers, presentations, and websites.• Spearheaded the development of provisional patent applications.

A biotech startup with the goal of curing age-related diseases and extending lifespan by increasing the activity of the protein SIRT6 with mRNA technology. https://www.sirtlabcorp.com • Secured a $900,000 grant from the Bird Foundation by partnering with a US pharmaceutical company.• Scouted and negotiated licensing agreements for external complementary technologies (such as mRNA and Lipid-Nanoparticles).• Conducted a comprehensive analysis of the markets and made significant contributions to our business strategy. • Performed an in-depth Competitive Analysis to demonstrate the relative benefits of our drug.• Led the creation of provisional patent applications.• Contributed to planning our drug development roadmap up to clinical trial.

Provides end-to-end, fully integrated drug development and manufacturing solutions and services to biotechnology and pharmaceutical companies.• Managed the Cocoon® Platform Project for automated cancer immunotherapy manufacturing in Israel. Successfully led it to the first human trial at Sheba Medical Center.• Managed five employees at Sheba Medical Center (Matrix management). I optimized work processes to comply with regulatory requirements (GLP guidelines) and trained lab employees in clean room operations.• Collaborated with Israeli and foreign entities to deliver innovative solutions under tight deadlines.

A global pharma company focused on providing access to highly innovative therapies in international markets.• Collaborated with the Business Development team to perform market analysis and engage with key opinion leaders to introduce new drugs and medical technologies to the market.• Traveled to receive training from international companies such as Biogen and Amgen and subsequently provided scientific training to the marketing team in Israel.• Reviewed and approved all marketing and scientific materials for the company's neurology and cardiology departments.• Created strong working relationships with key opinion leaders (neurologists and cardiologists).• Delivered medical presentations in leading medical centers.• Promoted and planned new clinical trials in Israel.• Submitted new drugs, like Repatha® by Amgen, to the Israeli healthcare basket committee.

A privately held Life Science company providing innovative, high-quality products and services for research, diagnostic, and clinical use.• Doubled annual sales revenue by tapping into a previously unexplored market segment and utilizing a consultative sales approach.• Awarded Salesman of the Year 2015 for Highest Sales and Best Sales Improvement.• To enter the biotech market, I offered scientific guidance to assist companies in carrying out large and complex projects. Furthermore, I facilitated connections with CRO companies that could help them overcome any performance hurdles. As a result, these companies chose to buy our products to run their projects.

• Students' Immunology Course Evaluation scores have increased significantly over the years of my teaching, from 3.3 in 2011 to 4.7 in 2015, on a 1 to 5 scale.

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented Veto Cell technology* represents a breakthrough in immune system management – safe and selective “tolerizing” of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats.The company’s intellectual property is based on innovative research from the laboratory of Professor Yair Reisner, Weizmann Institute of Science. I was part of the research team during my M.Sc. and Ph.D. https://www.cell-source.com/ • Assisted in translating immuno-oncology research into a successful clinical protocol tested in US trials.

• Recruited speakers and supervised the quality and content of the lectures.• Presented sixteen lectures myself. The topics covered include immunotherapy, autoimmunity, transplantation neuroimmunology, and vaccinations.

The Davidson Institute of Science Education nurtures the scientific education of students in Israel.

ISEF scholars carry the “Yes I Can” message to over 3,400 teens in development towns and urban neighborhoods, through science and math enrichment, tutoring and homework help ISEF scholars help the teens finish high school and qualify to go to college.• Mentored outstanding students from the Ethiopian community in Science and English.